Target intelligence / Profile preview

Free fatty acid receptor (FFAR) (FFAR)

Target
FFAR
Molecular classification
G protein-coupled receptor, Receptor
01

Overview

The Free fatty acid receptor (FFAR) family consists of G protein-coupled receptors (GPCRs) that act as nutrient sensors by responding to non-esterified fatty acids of various chain lengths. This family includes FFAR1 (GPR40) and FFAR4 (GPR120), which are activated by medium- and long-chain fatty acids to promote insulin secretion and anti-inflammatory signaling, as well as FFAR2 (GPR43) and FFAR3 (GPR41), which sense short-chain fatty acids produced by gut microbiota. These receptors play crucial roles in maintaining metabolic homeostasis and regulating immune responses, making them significant therapeutic targets for metabolic and inflammatory diseases. FFAR1, in particular, has been extensively studied for its ability to enhance glucose-dependent insulin secretion without the high risk of hypoglycemia associated with other antidiabetic agents. However, drug development in this space has faced challenges, most notably concerns regarding hepatotoxicity that led to the termination of clinical programs for several early candidates.

Other names
GPR40GPR41GPR43GPR120FFA1FFA2FFA3FFA4G protein-coupled receptor 40G protein-coupled receptor 41G protein-coupled receptor 43G protein-coupled receptor 120Omega-3 fatty acid receptor
02

Mechanism of action

Agonism, Allosteric modulation

03

Biological functions

Signal transductionGlucose-stimulated insulin secretionMetabolic homeostasisImmune response regulationAnti-inflammatory responseLipid metabolismIncretin hormone secretion (GLP-1, GIP)Adipogenesis
04

Disease associations

Type 2 diabetesObesityInflammationNon-alcoholic fatty liver disease (NAFLD)Non-alcoholic steatohepatitis (NASH)Metabolic syndromeCardiovascular disease
05

Safety considerations

Hepatotoxicity (observed with fasiglifam)Risk of lipotoxicity with chronic modulationPotential for off-target effects due to high lipophilicity of synthetic agonistsGastrointestinal side effects
06

Interacting drugs

Fasiglifam (TAK-875)

7 more in the full profile.

07

Biomarkers

Plasma free fatty acid levelsGlucose-stimulated insulin secretion (GSIS)Hemoglobin A1c (HbA1c)Glucagon-like peptide-1 (GLP-1) levelsC-peptide levels

Beyond the preview

Go deeper on Free fatty acid receptor (FFAR) (FFAR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Free fatty acid receptor (FFAR) (FFAR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call